BBIO vs MEDP: Which Stock Is the Better Buy?
BridgeBio Pharma, Inc. and Medpace Holdings, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — BBIO vs MEDP, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| BridgeBio Pharma, Inc. (BBIO) | Medpace Holdings, Inc. (MEDP) | |
|---|---|---|
| Market cap | $13.3B | $13.3B |
| Revenue (latest FY) | $502.08M | $2.53B |
| Net income (latest FY) | $-724.93M | $451.12M |
| Revenue growth (5y CAGR) | 127.4% | 22.3% |
| Net margin | -144.4% | 17.8% |
| Return on equity | 34.7% | 98.3% |
| P/E ratio | — | 29.3 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 10 |
| Positive free cash flow | No | Yes |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full BBIO vs MEDP breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open BBIO's full financials → Open MEDP's full financials →More comparisons
Frequently asked questions
Which is bigger, BBIO or MEDP?
Medpace Holdings, Inc. is larger by market capitalization — $13.3B versus $13.3B.
Which grows faster, BBIO or MEDP?
Over the last five fiscal years, BridgeBio Pharma, Inc. grew revenue faster — 127.4%/yr versus 22.3%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.